Details of the Drug

General Information of Drug (ID: DMC0GSJ)

• Drug Name: Efavirenz
• Synonyms: EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1]

• Therapeutic Class: Anti-HIV Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 315.67
  Logarithm of the Partition Coefficient (xlogp); 4
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 40 - 55 hours [3]
  Metabolism: The drug is metabolized via the cytochrome P450 system []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.15214 micromolar/kg/day [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.005 mg/mL [2]
• Chemical Identifiers:
  Formula: C14H9ClF3NO2
  IUPAC Name: (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
  Canonical SMILES: C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
  InChI: InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
  InChIKey: XPOQHMRABVBWPR-ZDUSSCGKSA-N
• Cross-matching ID:
  PubChem CID: 64139
  ChEBI ID: CHEBI:119486
  CAS Number: 154598-52-4
  DrugBank ID: DB00625
  TTD ID: D07HVY
  VARIDT ID: DR00412
  INTEDE ID: DR0560
  ACDINA ID: D00222
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Modulator	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[11]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[12]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Gene/Protein Processing	[13]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[14]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Protein Interaction/Cellular Processes	[11]
Calnexin (CANX)	OTYP1F6J	CALX_HUMAN	Protein Interaction/Cellular Processes	[15]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Gene/Protein Processing	[11]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[16]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[16]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[17]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Efavirenz

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
MK-1439	DM215WE	Major	Increased metabolism of Efavirenz caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Efavirenz caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Fosamprenavir	DM4W9B3	Moderate	Increased metabolism of Efavirenz caused by Fosamprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Stavudine	DM6DEK9	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Stavudine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Efavirenz caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Tipranavir	DM8HJX6	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Emtricitabine	DMBMUWZ	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Emtricitabine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Dolutegravir	DMCZGRE	Major	Increased metabolism of Efavirenz caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Efavirenz caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Etravirine	DMGV8QU	Major	Increased metabolism of Efavirenz caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Zalcitabine	DMH7MUV	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Didanosine	DMI2QPE	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Lopinavir	DMITQS0	Major	Increased metabolism of Efavirenz caused by Lopinavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Amprenavir	DMLMXE0	Moderate	Increased metabolism of Efavirenz caused by Amprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Abacavir	DMMN36E	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Abacavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Darunavir	DMN3GCH	Moderate	Increased metabolism of Efavirenz caused by Darunavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Atazanavir	DMSYRBX	Moderate	Increased metabolism of Efavirenz caused by Atazanavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Maraviroc	DMTL94F	Major	Increased metabolism of Efavirenz caused by Maraviroc mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]

Coadministration of a Drug Treating the Disease Different from Efavirenz (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[22]
Tretinoin	DM49DUI	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Tretinoin.	Acne vulgaris [ED80]	[25]
Isotretinoin	DM4QTBN	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Isotretinoin.	Acne vulgaris [ED80]	[25]
Nicotinamide	DMUPE07	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Nicotinamide.	Acquired cutaneous blood vessel malformation [EF20]	[21]
Repaglinide	DM5SXUV	Moderate	Increased metabolism of Efavirenz caused by Repaglinide mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[28]
Pioglitazone	DMKJ485	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Pioglitazone.	Acute diabete complication [5A2Y]	[21]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Efavirenz caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[29]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ivosidenib.	Acute myeloid leukaemia [2A60]	[26]
Tagraxofusp	DM9HQ5U	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Efavirenz caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[30]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Idarubicin.	Acute myeloid leukaemia [2A60]	[26]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Daunorubicin.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Gilteritinib.	Acute myeloid leukaemia [2A60]	[26]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Oliceridine.	Acute pain [MG31]	[26]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Rivastigmine.	Alzheimer disease [8A20]	[25]
Donepezil	DMIYG7Z	Moderate	Increased metabolism of Efavirenz caused by Donepezil mediated induction of CYP450 enzyme.	Alzheimer disease [8A20]	[26]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Efavirenz and Metronidazole.	Amoebiasis [1A36]	[22]
Inotersen	DMJ93CT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Inotersen.	Amyloidosis [5D00]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ivabradine.	Angina pectoris [BA40]	[31]
Bepridil	DM0RKS4	Major	Decreased metabolism of Efavirenz caused by Bepridil mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[26]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Dronedarone.	Angina pectoris [BA40]	[25]
Nifedipine	DMSVOZT	Moderate	Increased metabolism of Efavirenz caused by Nifedipine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[26]
Bedaquiline	DM3906J	Major	Increased metabolism of Efavirenz caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[31]
Clorazepate	DMC3JST	Moderate	Increased metabolism of Efavirenz caused by Clorazepate mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[26]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Efavirenz caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[32]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Oxymetholone.	Aplastic anaemia [3A70]	[21]
Cilostazol	DMZMSCT	Moderate	Increased metabolism of Efavirenz caused by Cilostazol mediated induction of CYP450 enzyme.	Arterial occlusive disease [BD40]	[26]
Posaconazole	DMUL5EW	Moderate	Increased metabolism of Efavirenz caused by Posaconazole mediated induction of UGT.	Aspergillosis [1F20]	[33]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Levalbuterol.	Asthma [CA23]	[34]
Terbutaline	DMD4381	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Terbutaline.	Asthma [CA23]	[35]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Pirbuterol.	Asthma [CA23]	[35]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Salbutamol.	Asthma [CA23]	[36]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Formoterol.	Asthma [CA23]	[35]
Zileuton	DMVRIC2	Moderate	Increased metabolism of Efavirenz caused by Zileuton mediated induction of CYP450 enzyme.	Asthma [CA23]	[26]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[26]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[26]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Clavulanate	DM2FGRT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Clavulanate.	Bacterial infection [1A00-1C4Z]	[21]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Efavirenz caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Clarithromycin	DM4M1SG	Moderate	Increased metabolism of Efavirenz caused by Clarithromycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Trovafloxacin	DM6AN32	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[21]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[21]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Rabeprazole	DMMZXIW	Moderate	Increased metabolism of Efavirenz caused by Rabeprazole mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Minocycline	DMVN5OH	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Minocycline.	Bacterial infection [1A00-1C4Z]	[21]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Telithromycin.	Bacterial infection [1A00-1C4Z]	[26]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Retigabine.	Behcet disease [4A62]	[26]
Cariprazine	DMJYDVK	Moderate	Increased metabolism of Efavirenz caused by Cariprazine mediated induction of CYP450 enzyme.	Bipolar disorder [6A60]	[39]
Erdafitinib	DMI782S	Major	Increased metabolism of Efavirenz caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[40]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Efavirenz and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[41]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Efavirenz and Loperamide.	Bowel habit change [ME05]	[42]
Temozolomide	DMKECZD	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Temozolomide.	Brain cancer [2A00]	[21]
Lomustine	DMMWSUL	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Lomustine.	Brain cancer [2A00]	[21]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Eribulin.	Breast cancer [2C60-2C6Y]	[26]
Ixabepilone	DM2OZ3G	Moderate	Increased metabolism of Efavirenz caused by Ixabepilone mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[43]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Lapatinib.	Breast cancer [2C60-2C6Y]	[26]
HKI-272	DM6QOVN	Major	Increased metabolism of Efavirenz caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Efavirenz caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Exemestane	DM9HPW3	Moderate	Increased metabolism of Efavirenz caused by Exemestane mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[45]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Efavirenz caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[46]
Pralatrexate	DMAO80I	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Pralatrexate.	Breast cancer [2C60-2C6Y]	[21]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Efavirenz caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[47]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Efavirenz caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Efavirenz caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Letrozole	DMH07Y3	Moderate	Increased metabolism of Efavirenz caused by Letrozole mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[26]
Quinestrol	DMJ6H1Z	Moderate	Increased metabolism of Efavirenz caused by Quinestrol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[46]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Tamoxifen.	Breast cancer [2C60-2C6Y]	[26]
Cabazitaxel	DMPAZHC	Moderate	Increased metabolism of Efavirenz caused by Cabazitaxel mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[48]
Bosutinib	DMTI8YE	Major	Increased metabolism of Efavirenz caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[49]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[21]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[21]
Estradiol	DMUNTE3	Moderate	Increased metabolism of Efavirenz caused by Estradiol mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[46]
Atorvastatin	DMF28YC	Moderate	Increased metabolism of Efavirenz caused by Atorvastatin mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[50]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[21]
Macitentan	DMP79A1	Moderate	Increased metabolism of Efavirenz caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[51]
Chenodiol	DMQ8JIK	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Chenodiol.	Cholelithiasis [DC11]	[21]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Efavirenz and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[52]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Efavirenz and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[34]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Efavirenz and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Efavirenz caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[32]
Dihydrocodeine	DMB0FWL	Moderate	Increased metabolism of Efavirenz caused by Dihydrocodeine mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[53]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Ketoprofen.	Chronic pain [MG30]	[21]
Regorafenib	DMHSY1I	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Regorafenib.	Colorectal cancer [2B91]	[21]
Irinotecan	DMP6SC2	Moderate	Increased metabolism of Efavirenz caused by Irinotecan mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[54]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Intedanib.	Colorectal cancer [2B91]	[21]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Isoproterenol.	Conduction disorder [BC63]	[35]
Drospirenone	DM1A9W3	Moderate	Increased metabolism of Efavirenz caused by Drospirenone mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[31]
Levonorgestrel	DM1DP7T	Moderate	Increased metabolism of Efavirenz caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[31]
Ulipristal	DMBNI20	Moderate	Increased metabolism of Efavirenz caused by Ulipristal mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[31]
Levobupivacaine	DM783CH	Minor	Increased metabolism of Efavirenz caused by Levobupivacaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[55]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Halothane.	Corneal disease [9A76-9A78]	[26]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Efavirenz and Propofol.	Corneal disease [9A76-9A78]	[56]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Sevoflurane.	Corneal disease [9A76-9A78]	[26]
Alfentanil	DMVO0UB	Moderate	Increased metabolism of Efavirenz caused by Alfentanil mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[57]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Probucol.	Coronary atherosclerosis [BA80]	[26]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Clofazimine.	Crohn disease [DD70]	[26]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Mifepristone.	Cushing syndrome [5A70]	[25]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Pasireotide.	Cushing syndrome [5A70]	[26]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Osilodrostat.	Cushing syndrome [5A70]	[26]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Efavirenz caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[58]
Ivacaftor	DMZC1HS	Moderate	Increased metabolism of Efavirenz caused by Ivacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[59]
Ethanol	DMDRQZU	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Ethanol.	Cystitis [GC00]	[21]
MK-8228	DMOB58Q	Moderate	Accelerated clearance of Efavirenz due to the transporter induction by MK-8228.	Cytomegaloviral disease [1D82]	[22]
Rivaroxaban	DMQMBZ1	Moderate	Accelerated clearance of Efavirenz due to the transporter induction by Rivaroxaban.	Deep vein thrombosis [BD71]	[60]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Sertraline.	Depression [6A70-6A7Z]	[26]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Trimipramine.	Depression [6A70-6A7Z]	[26]
Vilazodone	DM4LECQ	Moderate	Increased metabolism of Efavirenz caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[61]
Nefazodone	DM4ZS8M	Moderate	Increased metabolism of Efavirenz caused by Nefazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[26]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Efavirenz caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[62]
Milnacipran	DMBFE74	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Milnacipran.	Depression [6A70-6A7Z]	[21]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Escitalopram.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Clomipramine.	Depression [6A70-6A7Z]	[26]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Trazodone.	Depression [6A70-6A7Z]	[26]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Doxepin.	Depression [6A70-6A7Z]	[26]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Maprotiline.	Depression [6A70-6A7Z]	[26]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[21]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Increased metabolism of Efavirenz caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[63]
Oxybutynine	DMJPBAX	Moderate	Increased metabolism of Efavirenz caused by Oxybutynine mediated induction of CYP450 enzyme.	Discovery agent [N.A.]	[26]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Deutetrabenazine.	Dystonic disorder [8A02]	[26]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ingrezza.	Dystonic disorder [8A02]	[26]
Diazepam	DM08E9O	Moderate	Increased metabolism of Efavirenz caused by Diazepam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Zonisamide	DM0DTF7	Moderate	Increased metabolism of Efavirenz caused by Zonisamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[64]
Primidone	DM0WX6I	Moderate	Increased metabolism of Efavirenz caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Felbamate	DM1V5ZS	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[21]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Efavirenz caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Efavirenz caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[66]
Tiagabine	DMKSQG0	Moderate	Increased metabolism of Efavirenz caused by Tiagabine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Efavirenz caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Efavirenz caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Efavirenz caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Clonazepam	DMTO13J	Moderate	Increased metabolism of Efavirenz caused by Clonazepam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Efavirenz caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Ethotoin	DMXWOCP	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[21]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Efavirenz caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Cannabidiol.	Epileptic encephalopathy [8A62]	[31]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Mefenamic acid.	Female pelvic pain [GA34]	[21]
Dantrolene	DM1D8XY	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Dantrolene.	Fever [MG26]	[21]
Praziquantel	DMOU1PK	Moderate	Increased metabolism of Efavirenz caused by Praziquantel mediated induction of CYP450 enzyme.	Flatworm infection [1F70-1F86]	[67]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Efavirenz caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[68]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Efavirenz caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[69]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Solifenacin.	Functional bladder disorder [GC50]	[26]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Efavirenz caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[70]
Tolterodine	DMSHPW8	Moderate	Increased metabolism of Efavirenz caused by Tolterodine mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[26]
Itraconazole	DMCR1MV	Moderate	Increased metabolism of Efavirenz caused by Itraconazole mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[22]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Pentamidine.	Fungal infection [1F29-1F2F]	[26]
Terbinafine	DMI6HUW	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Terbinafine.	Fungal infection [1F29-1F2F]	[21]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ketoconazole.	Fungal infection [1F29-1F2F]	[26]
Atovaquone	DMY4UMW	Major	Increased metabolism of Efavirenz caused by Atovaquone mediated induction of UGT.	Fungal infection [1F29-1F2F]	[26]
Ripretinib	DM958QB	Moderate	Increased metabolism of Efavirenz caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[22]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[26]
Avapritinib	DMK2GZX	Major	Increased metabolism of Efavirenz caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[31]
Colchicine	DM2POTE	Moderate	Increased metabolism of Efavirenz caused by Colchicine mediated induction of CYP450 enzyme.	Gout [FA25]	[26]
Ergotamine	DMKR3C5	Major	Decreased metabolism of Efavirenz caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[26]
Boceprevir	DMBSHMF	Moderate	Increased metabolism of Efavirenz caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[71]
Lamivudine	DMI347A	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Lamivudine.	Hepatitis virus infection [1E50-1E51]	[21]
Simeprevir	DMLUA9D	Major	Increased metabolism of Efavirenz caused by Simeprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[72]
Telaprevir	DMMRV29	Moderate	Increased metabolism of Efavirenz caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[73]
Daclatasvir	DMSFK9V	Major	Increased metabolism of Efavirenz caused by Daclatasvir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[31]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[21]
Isoniazid	DM5JVS3	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[21]
Rifampin	DMA8J1G	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[74]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Efavirenz caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Pretomanid	DMDYA31	Major	Increased metabolism of Efavirenz caused by Pretomanid mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[75]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[21]
Simvastatin	DM30SGU	Moderate	Increased metabolism of Efavirenz caused by Simvastatin mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[50]
Fluvastatin	DM4MDJY	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Fluvastatin.	Hyper-lipoproteinaemia [5C80]	[21]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[21]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Efavirenz and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[76]
Rosuvastatin	DMMIQ7G	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Rosuvastatin.	Hyper-lipoproteinaemia [5C80]	[21]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Efavirenz and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[25]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Efavirenz and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[77]
Moexipril	DM26E4B	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Moexipril.	Hypertension [BA00-BA04]	[21]
Captopril	DM458UM	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Captopril.	Hypertension [BA00-BA04]	[21]
Methyldopa	DM5I621	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Methyldopa.	Hypertension [BA00-BA04]	[21]
Losartan	DM72JXH	Moderate	Increased metabolism of Efavirenz caused by Losartan mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[26]
Levamlodipine	DM92S6N	Moderate	Increased metabolism of Efavirenz caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[26]
Verapamil	DMA7PEW	Moderate	Increased metabolism of Efavirenz caused by Verapamil mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[26]
Perindopril	DMOPZDT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Perindopril.	Hypertension [BA00-BA04]	[21]
Felodipine	DMOSW35	Moderate	Increased metabolism of Efavirenz caused by Felodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[26]
Quinapril	DMR8H31	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Quinapril.	Hypertension [BA00-BA04]	[21]
Lisinopril	DMUOK4C	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Lisinopril.	Hypertension [BA00-BA04]	[21]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Efavirenz caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[78]
Tolvaptan	DMIWFRL	Moderate	Increased metabolism of Efavirenz caused by Tolvaptan mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[31]
Fludrocortisone	DMUDIR8	Moderate	Increased metabolism of Efavirenz caused by Fludrocortisone mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[26]
Pirfenidone	DM6VZFQ	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Pirfenidone.	Idiopathic interstitial pneumonitis [CB03]	[21]
Vitamin B3	DMQVRZH	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Vitamin B3.	Inborn lipid metabolism error [5C52]	[21]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[21]
Febuxostat	DMDEXQ0	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Febuxostat.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[21]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Efavirenz caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[79]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[21]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Efavirenz caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[80]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Efavirenz caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[81]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Efavirenz caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[32]
Ramelteon	DM7IW9J	Moderate	Increased metabolism of Efavirenz caused by Ramelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[82]
Triazolam	DMETYK5	Major	Increased plasma concentrations of Efavirenz and Triazolam due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[26]
Zaleplon	DMGFWSM	Minor	Increased metabolism of Efavirenz caused by Zaleplon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[83]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Efavirenz caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[84]
ITI-007	DMUQ1DO	Major	Increased metabolism of Efavirenz caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[85]
Quazepam	DMY4D87	Moderate	Increased metabolism of Efavirenz caused by Quazepam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Estazolam	DMZGXUM	Moderate	Increased metabolism of Efavirenz caused by Estazolam mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[25]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Phenolphthalein.	Irritable bowel syndrome [DD91]	[25]
Naloxegol	DML0B41	Moderate	Increased metabolism of Efavirenz caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[86]
Pemigatinib	DM819JF	Major	Increased metabolism of Efavirenz caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[31]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Crizotinib.	Lung cancer [2C25]	[26]
Brigatinib	DM7W94S	Major	Increased metabolism of Efavirenz caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[22]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Efavirenz and Porfimer Sodium.	Lung cancer [2C25]	[87]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ceritinib.	Lung cancer [2C25]	[26]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Efavirenz caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[88]
PF-06463922	DMKM7EW	Major	Increased metabolism of Efavirenz caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[89]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Alectinib.	Lung cancer [2C25]	[21]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Osimertinib.	Lung cancer [2C25]	[26]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and BIBW 2992.	Lung cancer [2C25]	[21]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Efavirenz caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[90]
Capmatinib	DMYCXKL	Major	Increased metabolism of Efavirenz caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[91]
Selpercatinib	DMZR15V	Major	Increased metabolism of Efavirenz caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[31]
Artemether	DM48QOT	Major	Increased metabolism of Efavirenz caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[22]
Proguanil	DMBL79I	Major	Increased metabolism of Efavirenz caused by Proguanil mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[26]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Halofantrine.	Malaria [1F40-1F45]	[92]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Hydroxychloroquine.	Malaria [1F40-1F45]	[26]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Sulphadoxine.	Malaria [1F40-1F45]	[21]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[26]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[21]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Idelalisib.	Mature B-cell leukaemia [2A82]	[93]
GDC-0199	DMH0QKA	Major	Increased metabolism of Efavirenz caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[94]
IPI-145	DMWA24P	Moderate	Increased metabolism of Efavirenz caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[95]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[26]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Efavirenz caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[96]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Clofarabine.	Mature B-cell lymphoma [2A85]	[97]
Blinatumomab	DMGECIJ	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Blinatumomab.	Mature B-cell lymphoma [2A85]	[21]
Ibrutinib	DMHZCPO	Moderate	Increased metabolism of Efavirenz caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[98]
Mercaptopurine	DMTM2IK	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[21]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Efavirenz caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[22]
Cytarabine	DMZD5QR	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Cytarabine.	Mature B-cell lymphoma [2A85]	[21]
Arry-162	DM1P6FR	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Arry-162.	Melanoma [2C30]	[21]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Vemurafenib.	Melanoma [2C30]	[26]
Selumetinib	DMC7W6R	Major	Increased metabolism of Efavirenz caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[99]
Ipilimumab	DMJTIYK	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Ipilimumab.	Melanoma [2C30]	[21]
Dacarbazine	DMNPZL4	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Dacarbazine.	Melanoma [2C30]	[21]
LGX818	DMNQXV8	Major	Increased metabolism of Efavirenz caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[100]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Efavirenz caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[31]
Estrone	DM5T6US	Moderate	Increased metabolism of Efavirenz caused by Estrone mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[46]
Ethinyl estradiol	DMODJ40	Moderate	Increased metabolism of Efavirenz caused by Ethinyl estradiol mediated induction of CYP450 enzyme.	Menopausal disorder [GA30]	[101]
Danazol	DML8KTN	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Danazol.	Menstrual cycle bleeding disorder [GA20]	[21]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Efavirenz caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[102]
Almogran	DM7I64Z	Moderate	Increased metabolism of Efavirenz caused by Almogran mediated induction of CYP450 enzyme.	Migraine [8A80]	[26]
Rimegepant	DMHOAUG	Major	Increased metabolism of Efavirenz caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[103]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Efavirenz caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[104]
Flibanserin	DM70DTN	Moderate	Increased metabolism of Efavirenz caused by Flibanserin mediated induction of CYP450 enzyme.	Mood disorder [6A60-6E23]	[105]
Midazolam	DMXOELT	Major	Increased plasma concentrations of Efavirenz and Midazolam due to competitive inhibition of the same metabolic pathway.	Mood/affect symptom [MB24]	[26]
Riluzole	DMECBWN	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Riluzole.	Motor neuron disease [8B60]	[21]
Carfilzomib	DM48K0X	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Carfilzomib.	Multiple myeloma [2A83]	[21]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Panobinostat.	Multiple myeloma [2A83]	[26]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Efavirenz and Thalidomide.	Multiple myeloma [2A83]	[106]
Elotuzumab	DMEYHG9	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Elotuzumab.	Multiple myeloma [2A83]	[21]
Tecfidera	DM2OVDT	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Tecfidera.	Multiple sclerosis [8A40]	[21]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Siponimod.	Multiple sclerosis [8A40]	[22]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ozanimod.	Multiple sclerosis [8A40]	[107]
Deflazacort	DMV0RNS	Major	Increased metabolism of Efavirenz caused by Deflazacort mediated induction of CYP450 enzyme.	Muscular dystrophy [8C70]	[31]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Romidepsin.	Mycosis fungoides [2B01]	[26]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Efavirenz caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Nilotinib.	Myeloproliferative neoplasm [2A20]	[26]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Efavirenz caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[108]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Dasatinib.	Myeloproliferative neoplasm [2A20]	[26]
Prasugrel	DM7MT6E	Minor	Decreased metabolism of Efavirenz caused by Prasugrel mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[31]
Modafinil	DMYILBE	Moderate	Increased metabolism of Efavirenz caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[26]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Promethazine.	Nausea/vomiting [MD90]	[26]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Efavirenz caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[31]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Granisetron.	Nausea/vomiting [MD90]	[26]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Dolasetron.	Nausea/vomiting [MD90]	[26]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Ondansetron.	Nausea/vomiting [MD90]	[26]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Efavirenz caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[31]
Bupropion	DM5PCS7	Moderate	Increased metabolism of Efavirenz caused by Bupropion mediated induction of CYP450 enzyme.	Nicotine use disorder [6C4A]	[22]
Entrectinib	DMMPTLH	Major	Increased metabolism of Efavirenz caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[109]
Orlistat	DMRJSP8	Moderate	Altered absorption of Efavirenz caused by Orlistat.	Obesity [5B80-5B81]	[110]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Levomethadyl Acetate.	Opioid use disorder [6C43]	[31]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Lofexidine.	Opioid use disorder [6C43]	[26]
S-297995	DM26IH8	Moderate	Increased metabolism of Efavirenz caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[31]
Naproxen	DMZ5RGV	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Naproxen.	Osteoarthritis [FA00-FA05]	[21]
Olaparib	DM8QB1D	Major	Increased metabolism of Efavirenz caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[22]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Rucaparib.	Ovarian cancer [2C73]	[26]
Etodolac	DM6WJO9	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Etodolac.	Pain [MG30-MG3Z]	[21]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Ibuprofen.	Pain [MG30-MG3Z]	[21]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Triclabendazole.	Parasitic worm infestation [1F90]	[26]
Istradefylline	DM20VSK	Moderate	Increased metabolism of Efavirenz caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[111]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Pimavanserin.	Parkinsonism [8A00]	[26]
Bromocriptine	DMVE3TK	Moderate	Increased metabolism of Efavirenz caused by Bromocriptine mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[26]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Apomorphine.	Parkinsonism [8A00]	[26]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Efavirenz caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[112]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Efavirenz and Famotidine.	Peptic ulcer [DA61]	[22]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Efavirenz caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[113]
Lefamulin	DME6G97	Major	Increased metabolism of Efavirenz caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[114]
Prednisone	DM2HG4X	Moderate	Increased metabolism of Efavirenz caused by Prednisone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[26]
Hydrocortisone	DMGEMB7	Moderate	Increased metabolism of Efavirenz caused by Hydrocortisone mediated induction of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[26]
Bromfenac	DMKB79O	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Bromfenac.	Postoperative inflammation [1A00-CA43]	[21]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Efavirenz caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[115]
Lonafarnib	DMGM2Z6	Major	Increased metabolism of Efavirenz caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[116]
Ritodrine	DM4V6RL	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ritodrine.	Preterm labour/delivery [JB00]	[35]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Degarelix.	Prostate cancer [2C82]	[26]
ABIRATERONE	DM8V75C	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and ABIRATERONE.	Prostate cancer [2C82]	[21]
Nilutamide	DMFN07X	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Nilutamide.	Prostate cancer [2C82]	[21]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Efavirenz caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[117]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Relugolix.	Prostate cancer [2C82]	[26]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Efavirenz caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[118]
Bicalutamide	DMZMSPF	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Bicalutamide.	Prostate cancer [2C82]	[21]
Silodosin	DMJSBT6	Moderate	Increased metabolism of Efavirenz caused by Silodosin mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[22]
Dutasteride	DMQ4TJK	Moderate	Increased metabolism of Efavirenz caused by Dutasteride mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[26]
Apremilast	DMTWS9E	Moderate	Increased metabolism of Efavirenz caused by Apremilast mediated induction of CYP450 enzyme.	Psoriasis [EA90]	[119]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Levomepromazine.	Psychotic disorder [6A20-6A25]	[26]
Ambrisentan	DMD1QXW	Moderate	Increased metabolism of Efavirenz caused by Ambrisentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[26]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Efavirenz caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[120]
Everolimus	DM8X2EH	Moderate	Accelerated clearance of Efavirenz due to the transporter induction by Everolimus.	Renal cell carcinoma [2C90]	[22]
Axitinib	DMGVH6N	Major	Increased metabolism of Efavirenz caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[121]
Temsirolimus	DMS104F	Moderate	Increased metabolism of Efavirenz caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[22]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[122]
Meloxicam	DM2AR7L	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Meloxicam.	Rheumatoid arthritis [FA20]	[21]
Upadacitinib	DM32B5U	Moderate	Increased metabolism of Efavirenz caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[123]
Tocilizumab	DM7J6OR	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Tocilizumab.	Rheumatoid arthritis [FA20]	[21]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Oxaprozin.	Rheumatoid arthritis [FA20]	[21]
Tofacitinib	DMBS370	Moderate	Increased metabolism of Efavirenz caused by Tofacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[22]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Flurbiprofen.	Rheumatoid arthritis [FA20]	[21]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Sulfasalazine.	Rheumatoid arthritis [FA20]	[21]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Sarilumab.	Rheumatoid arthritis [FA20]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Efavirenz and Leflunomide.	Rheumatoid arthritis [FA20]	[25]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Quetiapine.	Schizophrenia [6A20]	[26]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Mesoridazine.	Schizophrenia [6A20]	[25]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Thioridazine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Moderate	Increased metabolism of Efavirenz caused by Aripiprazole mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[124]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Iloperidone.	Schizophrenia [6A20]	[26]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Paliperidone.	Schizophrenia [6A20]	[26]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Perphenazine.	Schizophrenia [6A20]	[26]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Trifluoperazine.	Schizophrenia [6A20]	[26]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Risperidone.	Schizophrenia [6A20]	[26]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Amisulpride.	Schizophrenia [6A20]	[26]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Asenapine.	Schizophrenia [6A20]	[26]
Pimozide	DMW83TP	Major	Decreased metabolism of Efavirenz caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[125]
Fentanyl	DM8WAHT	Major	Increased metabolism of Efavirenz caused by Fentanyl mediated induction of CYP450 enzyme.	Sensation disturbance [MB40]	[25]
Avanafil	DM75CXN	Moderate	Increased metabolism of Efavirenz caused by Avanafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[126]
Tadalafil	DMJZHT1	Moderate	Increased metabolism of Efavirenz caused by Tadalafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[31]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Vardenafil.	Sexual dysfunction [HA00-HA01]	[26]
Voxelotor	DMCS6M5	Major	Increased metabolism of Efavirenz caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[127]
LDE225	DMM9F25	Major	Increased metabolism of Efavirenz caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[128]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Efavirenz caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[31]
Larotrectinib	DM26CQR	Moderate	Accelerated clearance of Efavirenz due to the transporter induction by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[22]
Methylprednisolone	DM4BDON	Moderate	Increased metabolism of Efavirenz caused by Methylprednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
PDX-101	DM6OC53	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and PDX-101.	Solid tumour/cancer [2A00-2F9Z]	[21]
Docetaxel	DMDI269	Moderate	Increased metabolism of Efavirenz caused by Docetaxel mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[129]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[31]
Armodafinil	DMGB035	Moderate	Increased metabolism of Efavirenz caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Efavirenz and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[26]
Etoposide	DMNH3PG	Moderate	Increased metabolism of Efavirenz caused by Etoposide mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
Prednisolone	DMQ8FR2	Moderate	Increased metabolism of Efavirenz caused by Prednisolone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[25]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Norethindrone	DMTY169	Moderate	Increased metabolism of Efavirenz caused by Norethindrone mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[101]
Taxol	DMUOT9V	Moderate	Increased metabolism of Efavirenz caused by Taxol mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[130]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[21]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Pitolisant.	Somnolence [MG42]	[26]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[26]
Disulfiram	DMCL2OK	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Disulfiram.	Substance abuse [6C40]	[21]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Naltrexone.	Substance abuse [6C40]	[131]
Warfarin	DMJYCVW	Moderate	Decreased metabolism of Efavirenz caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[26]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Efavirenz and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[132]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Efavirenz caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[133]
Eltrombopag	DMOGFIX	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Eltrombopag.	Thrombocytopenia [3B64]	[21]
Apixaban	DM89JLN	Moderate	Increased metabolism of Efavirenz caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[134]
Brilinta	DMBR01X	Moderate	Increased metabolism of Efavirenz caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[25]
Clopidogrel	DMOL54H	Moderate	Decreased metabolism of Efavirenz caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[135]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Lenvatinib.	Thyroid cancer [2D10]	[26]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Cabozantinib.	Thyroid cancer [2D10]	[26]
Methimazole	DM25FL8	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Methimazole.	Thyrotoxicosis [5A02]	[21]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Tizanidine.	Tonus and reflex abnormality [MB47]	[26]
Trimetrexate	DMDEA85	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Trimetrexate.	Toxoplasmosis [1F57]	[21]
Sirolimus	DMGW1ID	Moderate	Increased metabolism of Efavirenz caused by Sirolimus mediated induction of CYP450 enzyme.	Transplant rejection [NE84]	[22]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Tacrolimus.	Transplant rejection [NE84]	[26]
Saxagliptin	DMGXENV	Moderate	Increased metabolism of Efavirenz caused by Saxagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[136]
Linagliptin	DMWFJTR	Moderate	Increased metabolism of Efavirenz caused by Linagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[137]
Nitrofurantoin	DM7PQIK	Moderate	Increased risk of hepatotoxicity by the combination of Efavirenz and Nitrofurantoin.	Urinary tract infection [GC08]	[21]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Efavirenz caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[138]
Astemizole	DM2HN6Q	Major	Decreased metabolism of Efavirenz caused by Astemizole mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[26]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[139]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Procainamide.	Ventricular tachyarrhythmia [BC71]	[25]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Propafenone.	Ventricular tachyarrhythmia [BC71]	[26]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Flecainide.	Ventricular tachyarrhythmia [BC71]	[26]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Efavirenz and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[25]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Efavirenz 200 mg capsule	200 mg	Oral Capsule	Oral
Efavirenz 50 mg capsule	50 mg	Oral Capsule	Oral
Efavirenz 100 mg capsule	100 mg	Oral Capsule	Oral
Efavirenz 600 mg tablet	600 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
• [2] BDDCS applied to over 900 drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
• [7] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [8] Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
• [9] CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666.
• [10] Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
• [11] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [12] Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
• [13] Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicol Appl Pharmacol. 2011 Dec 1;257(2):227-34. doi: 10.1016/j.taap.2011.09.008. Epub 2011 Sep 19.
• [14] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [15] Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress. Br J Pharmacol. 2017 Dec;174(23):4409-4429. doi: 10.1111/bph.14045. Epub 2017 Nov 7.
• [16] Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
• [17] Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
• [18] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [19] Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
• [20] Duval X, Le Moing V, Longuet P, et al "Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir." Antimicrob Agents Chemother 44 (2000): 2593. [PMID: 11012391]
• [21] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [22] Cerner Multum, Inc. "Australian Product Information.".
• [23] Product Information. Dovato (dolutegravir-lamivudine). ViiV Healthcare, Research Triangle Park, NC.
• [24] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [25] Canadian Pharmacists Association.
• [26] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [27] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [28] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
• [29] Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [31] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [32] Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
• [33] Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
• [34] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [35] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [36] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
• [37] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [38] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [39] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [40] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [41] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [42] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [43] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [44] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [45] Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
• [46] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
• [47] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [48] Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
• [49] Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [50] Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
• [51] Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
• [52] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [53] Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
• [54] Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
• [55] Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
• [56] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [57] Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
• [58] Cerner Multum, Inc. "Canadian Product Information.".
• [59] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [60] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [61] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [62] Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [63] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
• [64] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
• [65] Anderson GD "Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs." Neurology 63(10 Suppl 4) (2004): S3-8. [PMID: 15557548]
• [66] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [67] Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
• [68] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [69] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [70] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [71] Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
• [72] Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
• [73] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [74] American Thoracic Society, CDC, Infectious Diseases Society of America "Treatment of tuberculosis." MMWR Morb Mortal Wkly Rep 52(RR-11) (2003): 1-77. [PMID: 12836625]
• [75] Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
• [76] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [77] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [78] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [79] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [80] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [81] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [82] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [83] Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [84] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [85] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [86] Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [87] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [88] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [89] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [90] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [91] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [92] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [93] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [94] Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
• [95] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [96] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [97] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [98] Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
• [99] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [100] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [101] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
• [102] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [103] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [104] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [105] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [106] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [107] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [108] Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
• [109] Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
• [110] MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
• [111] Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
• [112] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [113] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [114] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [115] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
• [116] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [117] Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
• [118] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [119] Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
• [120] Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
• [121] Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
• [122] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [123] Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
• [124] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [125] Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
• [126] Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
• [127] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [128] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [129] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [130] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
• [131] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [132] Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
• [133] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [134] Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
• [135] Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
• [136] Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
• [137] Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
• [138] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
• [139] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.